Medical congresses are among the most information-dense environments in life sciences. Within the span of three to five days, a single event can bring out pivotal clinical trial readouts, shift the scientific consensus in a therapeutic area, reveal a competitor's evolving narrative, and elevate a handful of emerging voices into influential KOLs. Yet for most organisations, a significant portion of that value goes uncaptured. ... Read this blog

In the life sciences industry, the companies who become successful aren't those with the greatest KOL networks but the ones that get their KOL management strategy right. They win because they built the right relationships, at the right stage, with the right depth of engagement. For mid-sized biopharma companies, this is the growth phase where that distinction matters most, where KOL strategy either becomes a genuine competitive advantage or never fully delivers. This guide breaks down exactly how to get it right and where to begin. ... Read this blog

Most life sciences teams already know who the top KOLs are in their therapeutic areas. The real challenge today is understanding which experts matter for which objective, when to engage them, and how to build meaningful relationships at scale. ... Read this blog

Most life sciences teams have a KOL strategy. Far fewer have one that holds up when the product pipeline expands, geographies multiply, and the same shortlist of familiar names stops being enough. ... Read this blog

A medical congress serves as one of the most valuable intelligence avenues of the year that life sciences teams look forward to. Three days of presentations, panels, late-breaking trials, and corridor conversations can shift the scientific narrative in a therapeutic area for the next few years. ... Read this blog

Most life sciences commercial teams still rely on legacy physician lists and outdated segmentation frameworks. In a landscape defined by scientific acceleration, specialized therapeutic areas, and multichannel HCP (Healthcare Professional) behavior, that approach creates blind spots. ... Read this blog

The period between regulatory submission and FDA approval is probably one of the most underutilised windows in life sciences. Most teams wait. But here is what the smartest medical affairs and commercial teams are doing during that window: they are identifying, engaging, and building trust with the clinicians who will drive adoption of their therapy at launch. ... Read this blog

Life sciences organizations invest millions in market research, competitive intelligence, and commercial analytics. Yet most are making critical decisions such as launch sequencing, MSL deployment, publication strategy, advisory board selection without knowing how they are perceived in the scientific discourse. ... Read this blog

Every major medical congress generates a flood of insights — scientific updates, competitor signals, and shifts in KOL influence. Yet within weeks, most of that intelligence is buried in notes, scattered across teams, or never translated into action. The difference comes down to one thing: how effectively you capture insights during sessions and run your post-congress debrief. ... Read this blog

Every major medical congress is a strategic inflection point for commercial teams in life sciences. Scientific narratives shift, new opinion leaders emerge, and competitive positioning takes shape in real time. However, what separates teams that extract real value from those that simply attend is intelligence. ... Read this blog

Two medical device companies launch similar products in the same therapeutic area. One achieves rapid clinical adoption. The other struggles to gain traction despite comparable clinical data. The difference is rarely the product. ... Read this blog

For life sciences organisations operating at scale, advisory boards are not a routine engagement activity, they are a strategic lever. ... Read this blog